UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

Launched by SHANGHAI LIFE SCIENCE & TECHNOLOGY · Apr 2, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the use of umbilical cord mesenchymal stem cells to treat patients who have left ventricular dysfunction after a heart attack, also known as an acute myocardial infarction. The goal of the study is to see if this treatment is safe and if it can help improve heart function. The trial is currently not recruiting participants, but it will involve patients aged between 18 and 90, regardless of gender.

To be eligible for the trial, patients must have experienced a severe heart attack and received emergency treatment within 12 hours. They should also have a specific level of heart function, as determined by tests, and show signs of heart damage. Participants will need to agree to the trial's procedures, understand the potential risks, and commit to following the treatment plan. However, individuals with certain health issues, such as serious liver or kidney problems, severe infections, or those who have other critical conditions, may not be eligible to join the study. If selected, participants can expect close monitoring and follow-up care during the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acute extensive anterior myocardial infarction were successfully treated with emergency interventional therapy within 12 hours after onset. LVEF was less than 0.35 by echocardiography 30 days after operation, scar area was more than 25% by MRI, and cardiac function was NYHA III-IV grade.
• • Fully inform the purpose, method and possible side effects of the test, agree to the test, and sign an informed consent form;
• • Good compliance, willing to take drugs and follow up according to the requirements of the plan;
• • Life expectancy exceeds one year.
• Exclusion Criteria:
• • Those who cannot tolerate cell therapy;
• • Patients with severe hepatic and renal insufficiency (ALT\>1.5 times the upper limit of normal value, Cr \>1.5 times the upper limit of normal value);
• • Patients with malignant tumors or extremely weak patients;
• • Patients with severe infection;
• • Patients who are expected to have the second coronary intervention or bypass grafting within 3 months;
• • Patients with other serious systemic diseases and organ dysfunction;
• • Patients with cardiogenic shock;
• • Patients with hemorrhagic diseases;
• • Researchers believe that anyone who is not suitable for inclusion